Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by longterm56on Apr 18, 2021 8:58pm
106 Views
Post# 33019924

RE:RE:RE:RE:RE:RE:RE:RE:RE:Board chair at ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:Board chair at ONCIt was me ... and I was limited in the responses because the "free" survey monkey survey was limited to 40 responses, so there may be even more shares represented here. 

Here was the result of 40 responses:

12,766,606

total without SPCEO


Our conclusion at the time (with 77,000,000 outstaning shares) was that with SPCEO we represented ~32%.  

Personally, I have added more since the survey, and others have posted here the same.  

Since survey monkey won't allow us to finish the job, we could try this ... 

Send an e-mail to anonymous0126@yahoo.com  with "THTX Shares: nnnn" as the subject, where nnnn is the # of shares you can influence.  I'll tally the results and post them here.  I promise I will not use or sell your e-mail address   ;) 

  -LT




Wino115 wrote: LT, was it you who tallied up the % ownership a while back or was that reality, palinc, scarlet, or someone else. It would be useful to dig that back out to see what that number was. 

longterm56 wrote: This has been a very enlightening discussion thread. It is obvious that if any serious LARGE investor did a little research on the make-up of the BOD, they would quickly conclude that THTX was not prepared to handle such a potential in their pipeline and simply find another alternative ... since there are hundreds of options out there.  We may have identified not only A problem, but THE problem! 

Another result of this discussion ... I convinced a friend today to invest a bit more in THTX but I think I will have them postpone that purchase until we see an attempt to fix this problem (just like the large investors are probably doing).

I'm in!!

   -LT 


Wino115 wrote: " If the company is going to have important developments totally ignored, what chance do we shareholders have of success????"
 




<< Previous
Bullboard Posts
Next >>